Alkermes sees fiscal 1st-qtr net income of $8.7M

Massachusetts, USA-based Alkermes says that, in the three months ended June 30, 2007, its net income totaled $8.7 million, or $0.08 per share, versus a loss of $700,000, or $0.01 per share, in the like, year-ago period.

Revenues during what is the first quarter of its fiscal year 2008, reached $68.9 million vs $51.5 million, as total manufacturing income amounted to $31.5 million, consisting of $30.2 million vs $19.1 million for Risperdal Consta (risperidone long-acting injection) for the treatment of schizophrenia and $1.3 million vs $3.1 million for Vivitrol, an extended-release injectable suspension of naltrexone for the treatment of alcohol dependence co-developed with USA-based Cephalon.

During the period, royalty revenues were $7.0 million based on US health care major Johnson & Johnson's Risperdal Consta sales of $278.7 million vs $5.1 million in the fiscal first-quarter 2007 on sales of $205.2 million.